Literature DB >> 628374

Treatment of hypoparathyroid patients with chlorthalidone.

R H Porter, B G Cox, D Heaney, T H Hostetter, B J Stinebaugh, W N Suki.   

Abstract

In an effort to maintain normal serum calcium levels without inducing hypercalciuria, we treated seven hypoparathyroid patients for up to 25 months with chlorthalidone, a thiazide-like sulfonamide diuretic, plus a salt-restricted diet, without added vitamin D. Mean 24-hour calcium excretion decreased from 179 to 88 mg (P less than 0.001), and mean serum calcium increased from 8.2 to 9.3 mg per deciliter (P less than 0.05). Diuretic therapy or moderate salt restriction alone was not as effective as combined therapy. Beneficial effects were sustained for as long as therapy was maintained. The rise in serum calcium, which involves the filterable and ionized fractions, cannot be due entirely to reduced excretion and may in part be explained by increased intestinal absorption. Oral chlorthalidone plus a low salt diet appears to be an effective alternative to vitamin D in the maintenance therapy of at least some patients with hypoparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 628374     DOI: 10.1056/NEJM197803162981101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  11 in total

1.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

2.  Metabolic causes of nephrolithiasis.

Authors:  D J Sherrard
Journal:  West J Med       Date:  1983-04

3.  Effect of bendrofluazide on calcium reabsorption in hypoparathyroidism.

Authors:  G H Newman; M Wade; D J Hosking
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats.

Authors:  David A Bushinsky; Thomas Willett; John R Asplin; Christopher Culbertson; Sara P Y Che; Marc Grynpas
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

Review 5.  Effects of antihypertensive drugs on endocrine function.

Authors:  E P Brass
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

6.  Long-term follow-up of patients with hypoparathyroidism.

Authors:  Deborah M Mitchell; Susan Regan; Michael R Cooley; Kelly B Lauter; Michael C Vrla; Carolyn B Becker; Sherri-Ann M Burnett-Bowie; Michael Mannstadt
Journal:  J Clin Endocrinol Metab       Date:  2012-10-05       Impact factor: 5.958

7.  Primary hyperparathyroidism and thiazide diuretics.

Authors:  P S Klimiuk; M Davies; P H Adams
Journal:  Postgrad Med J       Date:  1981-02       Impact factor: 2.401

Review 8.  Management of Hypoparathyroidism: Present and Future.

Authors:  John P Bilezikian; Maria Luisa Brandi; Natalie E Cusano; Michael Mannstadt; Lars Rejnmark; René Rizzoli; Mishaela R Rubin; Karen K Winer; Uri A Liberman; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2016-03-03       Impact factor: 5.958

Review 9.  MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.

Authors:  Jens Bollerslev; Camilla Schalin-Jäntti; Lars Rejnmark; Heide Siggelkow; Hans Morreau; Rajesh Thakker; Antonio Sitges-Serra; Filomena Cetani; Claudio Marcocci
Journal:  Eur J Endocrinol       Date:  2019-06-01       Impact factor: 6.664

Review 10.  Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus.

Authors:  Aliya A Khan; Christian A Koch; Stan Van Uum; Jean Patrice Baillargeon; Jens Bollerslev; Maria Luisa Brandi; Claudio Marcocci; Lars Rejnmark; Rene Rizzoli; M Zakarea Shrayyef; Rajesh Thakker; Bulent O Yildiz; Bart Clarke
Journal:  Eur J Endocrinol       Date:  2019-03       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.